immunology biosimilar
Scope
Date
~
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Samsung Biologics eye record-high annual sales
South Korea’s two major biopharmaceutical companies, Celltrion Inc. and Samsung Biologics Co., are respectively expecting more than 2 trillion...
Jul 08, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language -
Bio & Pharma
Celltrion to sell biosimilar products via its own channel in Europe
South Korea's biopharmaceutical company Celltrion Inc. plans to sell all of its biosimilar products through its own sales channels in Europe to impr...
May 11, 2022 (Gmt+09:00)
-
Pharmaceuticals
Samsung Bioepis to double biosimilars, may resume Nasdaq listing plans
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, plans to double the number of its biosimilar products on sale to 10 by 2025 and acce...
Feb 24, 2022 (Gmt+09:00)
-
Pharmaceuticals
Samsung Bioepis posts $1.26 billion in global biosimilar sales
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said on Friday that sales of its five biosimilar products in global markets, excludi...
Feb 18, 2022 (Gmt+09:00)
-
Biotech
Celltrion looks beyond biosimilars to develop its own mRNA drugs
South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...
Nov 16, 2021 (Gmt+09:00)
-
Biosimilars
Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
Sep 23, 2021 (Gmt+09:00)
-
Biosimilars
Samsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe
South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...
Aug 23, 2021 (Gmt+09:00)
language -
Biosimilars
Korean drugmakers race to release Stelara biosimilars
South Korea’s major drugmakers such as Celltrion Inc., Samsung Bioepis and Dong-A St are going for broke to release biosimilars of Stelara, Jo...
Jul 22, 2021 (Gmt+09:00)
language -
Biosimilars
Celltrion, Samsung Bioepis anticipate increased biosimilar sales in Europe
South Korean biosimilar companies such as Celltrion Inc. and Samsung Bioepis Co. are likely to see their sales hike by tens of millions of dollars...
Jul 12, 2021 (Gmt+09:00)